|
Status |
Public on Nov 20, 2021 |
Title |
Control 2 |
Sample type |
RNA |
|
|
Source name |
Plasma
|
Organism |
Homo sapiens |
Characteristics |
disease state: healthy patient: M02
|
Extracted molecule |
total RNA |
Extraction protocol |
Isolation using Plasma/Serum Circulating and Exosomal RNA Purification Kit (Slurry Format, #51000, Norgen Biotek, Canada)
|
Label |
fluorescence
|
Label protocol |
1000 attomol of spike-in-miRNA-Oligos osa-miR414 and cel-miR-254
|
|
|
Hybridization protocol |
total miRNA isolated from patient plasma was analyzed by the human v3 miRNA expression assay kit code set (Nanostring Tech.)
|
Scan protocol |
n.a.
|
Description |
total miRNA isolated from patient plasma was analyzed by the human v3 miRNA expression assay kit code set (Nanostring Tech.)
|
Data processing |
Background subtraction and quality control for 800 miRNAs tested in each sample were performed using the nSolver Software (Nanostring Tech., USA). Low abundant miRNAs with expression levels equivalent to the expression rates of negative controls were excluded from downstream analysis. All samples were normalized using the geometric mean of the two spike-in miRNA Oligos cel-miR-254 and osa-miR-414, and three positive ligation controls provided in the Code set.
|
|
|
Submission date |
Nov 05, 2021 |
Last update date |
Nov 20, 2021 |
Contact name |
Tilo Thottakara |
Organization name |
Universität Hamburg
|
Department |
Kardiologie
|
Lab |
AG Patten
|
Street address |
Martinistr 52
|
City |
Hamburg |
ZIP/Postal code |
20246 |
Country |
Germany |
|
|
Platform ID |
GPL30934 |
Series (1) |
GSE188324 |
A novel miRNA screen identifies miRNA-4454 as a candidate biomarker for ventricular fibrosis in patients with hypertrophic cardiomyopathy |
|